PanayiotisSSavvidesMD

Oncology • Phoenix, AZ

Associate Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Savvides is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Savvides' full profile

Already have an account?

Office
625 N 6th St
Phoenix, AZ 85004
Phone+1 602-406-8222

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2003
Mount Auburn HospitalResidency, Internal Medicine, 2000 - 2002
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
University of AthensClass of 1986

Certifications & Licensure

HI State Medical License 2024 - 2026
AZ State Medical License 2015 - 2025
CO State Medical License 2024 - 2025
OH State Medical License 2003 - 2016
MA State Medical License 2001 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 1
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer Start of enrollment: 2003 Feb 01
Completed
Phase 2
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer Start of enrollment: 2003 Nov 01
Terminated
Phase 1, Phase 2
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma Start of enrollment: 2004 Dec 01
Withdrawn
Not Applicable
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors Start of enrollment: 2005 Nov 01
Completed
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 3
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2007 Nov 19
COMPLETED
PHASE2
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors Start of enrollment: 2007 Aug 16
Completed
Phase 1
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck Start of enrollment: 2011 Jan 01
Terminated
Phase 2
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) Start of enrollment: 2011 Aug 01
Terminated
Phase 1, Phase 2
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2014 Apr 14
Completed
Phase 1
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Start of enrollment: 2021 Jul 23
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.
Athanassios Argiris, Yael Flamand, Panayiotis Savvides, Jennifer M Johnson, Ioannis Vathiotis
European Journal of Cancer. 2024-03-01
Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary center.
Chadi N Abdel-Halim, Thomas J O'Byrne, Jeffrey P Graves, Christeebella O Akpala, Eric J Moore
Oral Oncology. 2023-11-01
18 citations
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
Nathan Y Yu, Todd A DeWees, Molly M Voss, William G Breen, Jennifer S Chiang
Clinical Lung Cancer. 2022-12-01

Press Mentions

OncLive® Presents Seven State of the Science Summit™ Meetings in MarchFebruary 26th, 2020

Grant Support

OSI-774 + Docetaxel + Radiation In Locally Advanced Head/Neck CancerNational Center For Research Resources2005–2006
Osi-774+Docetaxel+Radiation In Locally Advanced Squamous Cell Head/Neck CancerNational Center For Research Resources2004